Discuss Report Read Report
Study Findings Implications and Recommendations "Given the growing interest among pharmaceutical companies in promoting better outcomes...a focus on medication adherence is a natural fit."
About Capgemini and Healthprize

Capgemini Consulting is the global strategy and transformation
consulting organization og the Capgemini Group, specializing in
advising and supporting enterprises in significant transforma-
tion, from innovative strategy to execution and with an unstint-
ing focus on results. With the new digital economy creating
significant disruptions and opportunities, our global team of
over 3,600 talented individuals work with leading companies
and governments to master Digital Transformation, drawing on
our understanding of the digital economy and our leadership in
business transformation and organizational change.

Find out more at: www.capgemini-consulting.com.

With around 120,000 people in 40 countries, Capgemini is one
of the world's foremost providers of consulting, technology and
outsourcing services. The Group reported 2011 global revenues
of EUR 9.7 billion. Together with its clients, Capgemini creates
and delivers business and technology solutions that fit their
needs and drive the results they want. A deeply multicultural
organization, Capgemini has developed its own way of working,
the Collaborative business Experience™, and draws on
Rightshore©, its worldwide delivery model.

Learn more about us at www.capgemini.com.

Driving measurable medication adherence
with rewards, education, and fun!

Healthprize, an innovative leader in the medication adherence
space, offers and online and mobile platform that drives patient
engagement and adherence, leveraging modern insights from
behavioral economics and consumer marketing.

Healthprize understands that medication non-adherence is a
complex psychological phenomenon, often resistant to simple
reminders, cost reductions, and education.

For more information regarding Healthprize's adherence
platform, please visit www.HealthPrize.com or call

An Email is being sent. Please wait a moment.

Contact Info
Download Now
Executive Summary

Medication non-adherence is one of the most serious problem in healthcare, posing a heavy financial impact on all constituencies. On the coste side, the New England Healthcare Institute estimated that medication non-adherence is responsible for $290 billion in "otherwise avoidable medical spending" in the US alone each year.

On the pharmaceutical revenue side, however, the impact of medication non-adherence had yet to be accurately quantified. The market assumption relied upon to date, and quoted extensively, has been $30 billion globally, which we felt was a gross underestimate-prompting this project.

According to our analysis, the US pharmaceutical industry alone loses an estimated $188 billion anually due to medication non-adherence. This represents 59% of the $320 billion in total US pharmaceutical revenue in 2011, and 37% of the $508 billion annual potential total revenue.

Extrapolated to the global pharmaceutical market, revenue loss is estimated to be $564 billion, or 59% of the $956 billion in total global pharmaceutical revenue in 2011, and 37% of the $1,520 billion annual potential total revenue.

Interventions to improve medication adherence should be top priority for the pharmaceutical industry and will prove beneficial to all stakeholders. While achieving 100% medication adherence is not possible, even a modest 10 percentage point increase in adherence could lead to a significant rise in pharmaceutical revenues, accompanied by improved health outcomes and decreased healthcare spending.

Download Full Report
© 2014 HealthPrize Technologies Privacy | Terms | Contact